Sanyal will discuss retatrutide and nonalcoholic steatohepatitis (NASH) during Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor TriagonistObesity, NAFLD, and T2D Phase 2 Trial Results on Monday, June 26, at 1:30 p.m
The molecule is a peptide with an albumin-binding fatty acid chain, which means its vulnerable to thermal degradation, agitation, and freeze-thaw cycles
No clinical trial has evaluated retatrutide in women with PCOS, and no human efficacy or safety for a PCOS indication has been demonstrated
Several factors associated with GLP-1 use can contribute to this shift: Rapid weight loss Reduced caloric intake Potential nutrient deficiencies, especially protein, iron, and zinc Hormonal and metabolic changes These changes do not damage the hair follicle itself, which is why the condition is often reversible once the body stabilizes
By activating multiple pathways simultaneously, it aims to: Reduce appetite Slow gastric emptying Improve blood sugar control Increase fat metabolism Boost energy expenditure This multi-target approach differentiates it from current single- and dual-agonist obesity treatments
How To Get Started Schedule your initial appointment (45 mins) $395 Interested in learning more